AU2019344524B2 - Anti-KLRG1 antibodies - Google Patents

Anti-KLRG1 antibodies

Info

Publication number
AU2019344524B2
AU2019344524B2 AU2019344524A AU2019344524A AU2019344524B2 AU 2019344524 B2 AU2019344524 B2 AU 2019344524B2 AU 2019344524 A AU2019344524 A AU 2019344524A AU 2019344524 A AU2019344524 A AU 2019344524A AU 2019344524 B2 AU2019344524 B2 AU 2019344524B2
Authority
AU
Australia
Prior art keywords
seq
abc
klrg1
cdr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019344524A
Other languages
English (en)
Other versions
AU2019344524A1 (en
Inventor
Stefano V. Gulla
Evan Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Brigham and Women's Hospital Inc
Original Assignee
The Brigham and Women's Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Brigham and Women's Hospital Inc filed Critical The Brigham and Women's Hospital Inc
Publication of AU2019344524A1 publication Critical patent/AU2019344524A1/en
Assigned to THE BRIGHAM AND WOMEN’S HOSPITAL, INC. reassignment THE BRIGHAM AND WOMEN’S HOSPITAL, INC. Request for Assignment Assignors: ABCURO, INC.
Application granted granted Critical
Publication of AU2019344524B2 publication Critical patent/AU2019344524B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2019344524A 2018-09-17 2019-09-06 Anti-KLRG1 antibodies Active AU2019344524B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862732329P 2018-09-17 2018-09-17
US62/732,329 2018-09-17
PCT/US2019/050110 WO2020060781A1 (en) 2018-09-17 2019-09-06 Anti-klrg1 antibodies

Publications (2)

Publication Number Publication Date
AU2019344524A1 AU2019344524A1 (en) 2021-03-25
AU2019344524B2 true AU2019344524B2 (en) 2026-07-09

Family

ID=69887899

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019344524A Active AU2019344524B2 (en) 2018-09-17 2019-09-06 Anti-KLRG1 antibodies

Country Status (13)

Country Link
US (2) US12365735B2 (enExample)
EP (1) EP3852779A4 (enExample)
JP (2) JP7654548B2 (enExample)
KR (1) KR102934267B1 (enExample)
CN (2) CN112752580B (enExample)
AU (1) AU2019344524B2 (enExample)
BR (1) BR112021004553A2 (enExample)
CA (1) CA3113069A1 (enExample)
EA (1) EA202190647A1 (enExample)
IL (2) IL281594B2 (enExample)
MX (2) MX2021003119A (enExample)
SG (1) SG11202102114UA (enExample)
WO (1) WO2020060781A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3852779A4 (en) 2018-09-17 2022-06-08 Abcuro, Inc. ANTI-KLRG1 ANTIBODIES
US20230331853A1 (en) * 2020-09-11 2023-10-19 National Jewish Health Methods and compositions for treating respiratory diseases or conditions related to innate lymphoid cells
CA3212311A1 (en) 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
WO2022204529A1 (en) 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
US20260103525A1 (en) * 2022-09-27 2026-04-16 The Brigham And Women's Hospital, Inc. Klrg1 signalling therapy for infectious disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017210523A1 (en) * 2016-06-03 2017-12-07 The Brigham And Women's Hospital Klrg1 signaling therapy
WO2018053264A2 (en) * 2016-09-16 2018-03-22 The Brigham And Women's Hospital, Inc. Klrg1 depletion therapy

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
CA2595169A1 (en) 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
CA2673870A1 (en) * 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
WO2011016238A1 (en) 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
EP2611832B1 (en) * 2010-09-02 2017-11-29 Vaccinex, Inc. Anti-cxcl13 antibodies and methods of using the same
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
EP2699256B1 (en) 2011-04-21 2017-09-27 The Regents of the University of Colorado, a body corporate Compositions and methods for the treatment of neuromyelitis optica
ES2929575T3 (es) 2011-06-06 2022-11-30 Novo Nordisk As Anticuerpos terapéuticos
JPWO2012176765A1 (ja) * 2011-06-24 2015-02-23 株式会社ペルセウスプロテオミクス 抗ヒトｐ−カドへリン（ｃｄｈ３）遺伝子組み換え抗体
CA2904805A1 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
TW201622743A (zh) 2014-03-19 2016-07-01 財團法人臺灣基督長老教會馬偕紀念社會事業基金會馬偕紀念醫院 免疫原醣肽、包含該醣肽之組合物及其用途
WO2016009487A1 (ja) 2014-07-14 2016-01-21 三菱電機株式会社 空気調和装置
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
PE20181349A1 (es) 2015-10-07 2018-08-22 Hoffmann La Roche Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
JP7023853B2 (ja) 2016-03-04 2022-02-22 アレクトル エルエルシー 抗ｔｒｅｍ１抗体及びその使用方法
CA3049791A1 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
WO2018237341A1 (en) 2017-06-22 2018-12-27 Development Center For Biotechnology A TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT FOR CANCER THERAPY
US20210002373A1 (en) 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
EP3852779A4 (en) 2018-09-17 2022-06-08 Abcuro, Inc. ANTI-KLRG1 ANTIBODIES
MX2021012171A (es) 2019-04-09 2021-12-10 Abcuro Inc Anticuerpos reductores del miembro 1 de la subfamilia g de receptores similares a la lectina de linfocitos citoliticos (klrg1).
CA3212311A1 (en) 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017210523A1 (en) * 2016-06-03 2017-12-07 The Brigham And Women's Hospital Klrg1 signaling therapy
WO2018053264A2 (en) * 2016-09-16 2018-03-22 The Brigham And Women's Hospital, Inc. Klrg1 depletion therapy

Also Published As

Publication number Publication date
WO2020060781A1 (en) 2020-03-26
SG11202102114UA (en) 2021-04-29
IL281594B1 (en) 2025-10-01
US20210347899A1 (en) 2021-11-11
BR112021004553A2 (pt) 2021-06-08
JP2022501065A (ja) 2022-01-06
MX2025008993A (es) 2025-09-02
KR20210060477A (ko) 2021-05-26
KR102934267B1 (ko) 2026-03-05
JP2024156878A (ja) 2024-11-06
EP3852779A4 (en) 2022-06-08
EP3852779A1 (en) 2021-07-28
EA202190647A1 (ru) 2021-09-09
US12365735B2 (en) 2025-07-22
IL323170A (en) 2025-11-01
US20260125479A1 (en) 2026-05-07
IL281594B2 (en) 2026-02-01
MX2021003119A (es) 2021-05-14
IL281594A (en) 2021-05-31
JP7654548B2 (ja) 2025-04-01
CN112752580B (zh) 2024-12-13
CN119638835A (zh) 2025-03-18
CN112752580A (zh) 2021-05-04
AU2019344524A1 (en) 2021-03-25
CA3113069A1 (en) 2020-03-26

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

Free format text: FORMER APPLICANT(S): ABCURO, INC.